This Article Full Text Full Text (PDF) Purchase Article View Shopping Cart Alert me when this article is cited Alert me if a correction is posted Services Email this article to a colleague Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Save to my personal folders Download to citation manager Rights & Permissions Citing Articles Citing Articles via HighWire Citing Articles via Google Scholar Google Scholar Articles by Arteaga, C. L. Search for Related Content PubMed PubMed Citation Articles by Arteaga, C. L. Social Bookmarking                            What's this?

The Epidermal Growth Factor Receptor: From Mutant Oncogene in Nonhuman Cancers to Therapeutic Target in Human Neoplasia

From the Departments of Medicine and Cancer Biology and Vanderbilt-Ingram Cancer Center, Vanderbilt University School of Medicine, Nashville, TN.

Address correspondence to Carlos L. Arteaga, MD, Division of Hematology-Oncology, Vanderbilt University, 777 Preston Research Bldg, Nashville, TN 37232-6307; email: carlos.arteaga@ mcmail.vanderbilt.edu.

ABSTRACT: Approximately two decades ago, the epidermal growth factor receptor (EGFR) was discovered to be the proto-oncogene of the mutant, constitutively active oncogenic v-erbB tyrosine kinase, which induces avian erythroblastosis. Unlike the mutant oncogene, the EGFR requires activation by binding of ligand to its extracellular (EC) domain, whereas its cellular effects depend on activation of its cytoplasmic tyrosine kinase. The overexpression of EGFR and its ligands in several human carcinomas and their association with accelerated tumor progression provided a rationale for targeting this network with tumor-selective strategies. Two of those antireceptor approaches, both solidly based on the known structure and function of the EGFR, are discussed. The first strategy involves the development of humanized monoclonal antibodies against the nonconserved receptor’s EC domain. These antibodies block ligand binding and can induce receptor endocytosis and downregulation. The second approach is the generation of ATP mimetics that compete with ATP for binding to the receptor’s kinase pocket, thus disabling signal transduction. Preclinical and early clinical studies already suggest that both of these approaches, either alone or in combination with standard anticancer therapies, will be able to alter the natural history of EGFR-expressing cancers with little to no toxicity to the tumor-bearing host.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Facebook    Reddit    Technorati    Twitter    What's this?

This article has been cited by other articles:

				M. A. Socinski What Guides Decisions about the Use of Epidermal Growth Factor Receptor Antibody or Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Advanced Non-small Cell Lung Cancer? ASCO Educational Book, January 1, 2009; 2009(1): 436 - 443. [Abstract] [Full Text] [PDF]

				W. Zhang, M. Gordon, A. M. Schultheis, D. Y. Yang, F. Nagashima, M. Azuma, H.-M. Chang, E. Borucka, G. Lurje, A. E. Sherrod, et al. FCGR2A and FCGR3A Polymorphisms Associated With Clinical Outcome of Epidermal Growth Factor Receptor Expressing Metastatic Colorectal Cancer Patients Treated With Single-Agent Cetuximab J. Clin. Oncol., August 20, 2007; 25(24): 3712 - 3718. [Abstract] [Full Text] [PDF]

				P. A. Rascoe, X. Cao, J. C. Daniel, S. D. Miller, and W. R. Smythe Receptor tyrosine kinase and phosphoinositide-3 kinase signaling in malignant mesothelioma J. Thorac. Cardiovasc. Surg., August 1, 2005; 130(2): 393 - 400. [Abstract] [Full Text] [PDF]

				L. M. Ellis and P. M. Hoff Targeting the Epidermal Growth Factor Receptor: An Important Incremental Step in the Battle Against Colorectal Cancer J. Clin. Oncol., April 1, 2004; 22(7): 1177 - 1179. [Full Text] [PDF]

				M. G. Kris, R. B. Natale, R. S. Herbst, T. J. Lynch Jr, D. Prager, C. P. Belani, J. H. Schiller, K. Kelly, H. Spiridonidis, A. Sandler, et al. Efficacy of Gefitinib, an Inhibitor of the Epidermal Growth Factor Receptor Tyrosine Kinase, in Symptomatic Patients With Non-Small Cell Lung Cancer: A Randomized Trial JAMA, October 22, 2003; 290(16): 2149 - 2158. [Abstract] [Full Text] [PDF]

				V. A. Miller, D. H. Johnson, L. M. Krug, B. Pizzo, L. Tyson, W. Perez, P. Krozely, A. Sandler, D. Carbone, R. T. Heelan, et al. Pilot Trial of the Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Gefitinib Plus Carboplatin and Paclitaxel in Patients With Stage IIIB or IV Non-Small-Cell Lung Cancer J. Clin. Oncol., June 1, 2003; 21(11): 2094 - 2100. [Abstract] [Full Text] [PDF]

				Rolf. F. Barth, W. Yang, D. M. Adams, J. H. Rotaru, S. Shukla, M. Sekido, W. Tjarks, R. A. Fenstermaker, M. Ciesielski, M. M. Nawrocky, et al. Molecular Targeting of the Epidermal Growth Factor Receptor for Neutron Capture Therapy of Gliomas Cancer Res., June 1, 2002; 62(11): 3159 - 3166. [Abstract] [Full Text] [PDF]